Biologics currently dominate the market for disease-modifying drugs for rheumatoid arthritis, but companies are betting that there is room for next-generation oral drugs that target protein kinases.
Rights and permissions
About this article
Cite this article
Opar, A. Kinase inhibitors attract attention as oral rheumatoid arthritis drugs. Nat Rev Drug Discov 9, 257–258 (2010). https://doi.org/10.1038/nrd3155
Issue Date:
DOI: https://doi.org/10.1038/nrd3155
- Springer Nature Limited
This article is cited by
-
Genetic and clinical markers for predicting treatment responsiveness in rheumatoid arthritis
Frontiers of Medicine (2019)
-
DrugGenEx-Net: a novel computational platform for systems pharmacology and gene expression-based drug repurposing
BMC Bioinformatics (2016)
-
Mitogen-Activated Protein Kinases as Therapeutic Targets for Rheumatoid Arthritis
Drugs (2013)
-
A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis
Arthritis Research & Therapy (2011)
-
Induction of immune tolerance in the treatment of rheumatoid arthritis
Nature Reviews Rheumatology (2011)